Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 6/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.45 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.45 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.45 |
| ▸ | ST6GAL1 | P15907 | 5/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5505017 | 1.00 | TYMP (0.51) | TYMPLMNATHRBMTORMDM2 | |
| SCHEMBL1737308 | 0.92 | TYMP (0.54) | TYMPLMNATHRBMTORMDM2 | |
| SCHEMBL2401698 | 0.90 | LMNA (0.52) | TYMPLMNATHRBMTORMDM2 | |
| SCHEMBL2401695 | 0.90 | LMNA (0.52) | TYMPLMNATHRBMTORMDM2 | |
| SCHEMBL5710025 | 0.89 | TYMP (0.62) | TYMPLMNATHRBMTORMDM2 | |
| SCHEMBL17223094 | 0.88 | TYMP (0.51) | TYMPLMNATHRBMTORMDM2 | |
| SCHEMBL5505051 | 0.88 | TYMP (0.49) | TYMPLMNATHRBMTORMDM2 | |
| SCHEMBL5505049 | 0.88 | TYMP (0.49) | TYMPLMNATHRBMTORMDM2 | |
| SCHEMBL26647620 | 0.87 | TYMP (0.54) | TYMPLMNATHRBMTORMDM2 | |
| SCHEMBL31390283 | 0.85 | TYMP (0.49) | TYMPLMNATHRBMTORMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0977767-B1 | AMINOOXY-MODIFIED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS INC (US) | 2007-09-19 | — | — | EP | disclosed |
| US-6849723-B2 | Oligonucleotide analogs having modified dimers | ISIS PHARMACEUTICALS, INC. (US) | 2005-02-01 | — | — | US | disclosed |
| US-6639062-B2 | Oligonucleotides which elicit ribonuclease for cleavage in complementary nucleic acid strand, having increased binding affinity/nuclease resistance; for medical diagnosis, gene therapy | ISIS PHARMACEUTICALS, INC. | 2003-10-28 | — | — | US | disclosed |
| US-20030181693-A1 | Oligonucleotide analogs having modified dimers | COOK PHILLIP DAN (US) | 2003-09-25 | — | — | US | disclosed |
| US-20030088079-A1 | AMINOOXY-MODIFIED NUCLEOSIDIC COMPOUNDS AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | IONIS PHARMACEUTICALS, INC. | 2003-05-08 | — | — | US | disclosed |
| US-6420549-B1 | NUCLEOTIDE SEQUENCES FOR USE AS TOOLS IN GENETIC ENGINEERING AND CONTROLLING TRANSLATION | ISIS PHARMACEUTICALS, INC. | 2002-07-16 | — | — | US | disclosed |
| US-6194598-B1 | Aminooxy-modified oligonucleotide synthetic intermediates | ISIS PHARMACEUTICALS, INC. | 2001-02-27 | — | — | US | disclosed |
| US-6172209-B1 | MOLECULAR HYBRIDIZATION, GENETIC ENGINEERING; NUCLEASE RESISTANCE | ISIS PHARMACEUTICALS INC. | 2001-01-09 | — | — | US | disclosed |
| US-6127533-A | SPECIFICALLY HYBRIDIZABLE WITH A SELECTED SEQUENCE OF RNA OR DNA; DIAGNOSIS OF DISEASES | ISIS PHARMACEUTICALS, INC. (US) | 2000-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181693-A1 | Oligonucleotide analogs having modified dimers | RNASEL, ADAR, RNGTT | TYMP 20/4885LMNA 1778/4885THRB 2969/4885 |
| US-20030088079-A1 | AMINOOXY-MODIFIED NUCLEOSIDIC COMPOUNDS AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | HNRNPM, RNASEH1, HNRNPF | TYMP 127/4885LMNA 680/4885THRB 4144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.